Openbookopenbook
Equity
Charles River Laboratories(CRL)
USD --+0.00%
Reward50Moderate
Risk53Moderate
📊75%Data
Thin -4% profit margin
CRL
+0.0 · +0.00%
USD · NYSE
Charles River Laboratories | Healthcare
Earnings Deterioration
Market Cap:8.05Bn
ℹ️
Reward Rating
50
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
53
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on CRL to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $197.40.

What is Charles River Laboratories?

provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.

CRL · Verdict

Moderate reward · elevated risk

CRL stands out on valuation and cash flow, but watch the volatility signal.

Based on 88% data coverage

CRL · Verdict

What’s working & what to watch

Strengths 2

  • Valuation68/100

    P/E 16.7× · PEG 0.13

  • Cash flow65/100

    13% free-cash-flow margin

Watchouts 3

  • Volatility20/100

    Weak vs peers

  • Profitability25/100

    -4% net margin · -4% ROE

  • Balance sheet45/100

    Interest covered 4.7×

Model-based scoring. For information only — not financial advice.

What is Charles River Laboratories?

provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 8.05B.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (50)

The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap8.05B
P/E RatioN/A
Dividend YieldN/A
52 Week High228.88
52 Week Low91.8609
Last AnnualDecember
IPO Date6/23/2000
IncorporatedUSA
Shares Outstanding49M
No. of Employees18,300
IndustryDiagnostics & Research
ExchangeNYSE
Beta1.62
CurrencyUSD
Websitewww.criver.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.